Stock Traders Buy High Volume of Pfizer Call Options (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) was the target of some unusual options trading activity on Thursday. Stock traders bought 673,000 call options on the stock. This represents an increase of 584% compared to the average volume of 98,364 call options.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer raised its 2026 guidance to $62–$64 billion in revenue and adjusted EPS of $2.95–$3.05. In the third quarter, launched and acquired products grew 32% operationally, while non-COVID products grew 7%—supporting the company’s effort to diversify beyond pandemic products. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts raised their targets: Guggenheim moved to $33 and Scotiabank to $35, with both expressing bullish views. These targets signal potential upside if Pfizer delivers on its outlook. Guggenheim analyst update Scotiabank analyst update
• Neutral Sentiment: Pfizer reported progress in a Phase 3 study of its monthly obesity drug. The program could provide a competitive opportunity, but the update does not establish clinical success or commercial prospects. Article: Pfizer Advances Monthly Obesity Drug Study
• Neutral Sentiment: Analyst opinion remains mixed: Goldman Sachs maintained a Hold rating, while UBS and Citigroup raised their targets but kept Neutral ratings. Article: Goldman Sachs Remains a Hold on Pfizer
• Negative Sentiment: Investors may be weighing margin compression and continuing weakness in pandemic-related products against the raised forecast. Pfizer’s growth and portfolio transformation still need to translate into durable results, leaving execution a key concern. Article: Pfizer Just Raised Guidance. The Bigger Test Comes Next

Pfizer Stock Performance

Pfizer stock traded down $0.88 on Thursday, hitting $29.91. The company’s stock had a trading volume of 39,283,221 shares, compared to its average volume of 39,801,063. The firm has a market cap of $170.46 billion, a P/E ratio of 42.72, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The company has a fifty day moving average price of $28.69 and a 200-day moving average price of $26.86. Pfizer has a one year low of $23.62 and a one year high of $31.44. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 earnings per share. On average, equities analysts anticipate that Pfizer will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Guggenheim increased their price objective on shares of Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Cantor Fitzgerald increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $29.94.

Institutional Trading of Pfizer

Several large investors have recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC boosted its stake in Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC bought a new stake in shares of Pfizer during the second quarter worth $26,000. Field & Main Bank acquired a new stake in shares of Pfizer in the second quarter valued at $27,000. Bullseye Investment Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at $28,000. Finally, Timbuktu Capital Management LLC bought a new position in shares of Pfizer in the second quarter valued at about $29,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.